Original Publication Date: 13 January, 2014
Publication / Source: Future Oncology
Authors: Tamara MH Gall, Adam E Frampton, Jonathan Krell, Nagy A Habib, Leandro Castellano, Justin Stebbing & Long R Jiao
Detecting alterations in blood cell-free DNA (cfDNA) is hoped to be a novel, noninvasive method for diagnosing, prognosing and monitoring cancer patients. Several studies have assessed the usefulness of measuring tumor-specific genetic and epigenetic changes of cfDNA, such as loss of heterozygosity, frequency of mutations, alterations of microsatellites and the methylation of genes in patient blood samples.